XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Patent and Technology License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 06, 2020
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2021
Patent and Technology License Agreements [Line Items]            
Annual maintenance fee expense   $ 90,000 $ 90,000      
Annual minimum royalty payment       $ 100,000    
Increasing annual royalties       25,000    
Maximum aggregate annual royalties       150,000    
Payable amount to NAT       1,100,000    
Research and development expense       $ 2,621,910 $ 3,445,515  
Developmental milestone, description       NoveCite is obligated to pay Eterna up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Eterna an amount equal to a mid-twenties percentage of any sublicensee fees it receives.    
Revenue percentage       50.00%    
Upfront payment       $ 40,000,000    
Commercial milestone payments       $ 300,000,000    
Description of license agreement       The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.    
Minimum [Member]            
Patent and Technology License Agreements [Line Items]            
Development milestone payments       $ 40,000,000    
Percentages of net product sales       10.00%    
Minimum [Member] | Royalties [Member]            
Patent and Technology License Agreements [Line Items]            
Percentages of net product sales       10.00%    
Maximum [Member]            
Patent and Technology License Agreements [Line Items]            
Development milestone payments       $ 70,000,000    
Percentages of net product sales       15.00%    
Maximum [Member] | Royalties [Member]            
Patent and Technology License Agreements [Line Items]            
Percentages of net product sales       15.00%    
NoveCite [Member]            
Patent and Technology License Agreements [Line Items]            
Research and development expense           $ 5,000,000
Outstanding equity 25.00%          
Percentage of outstanding equity 75.00%          
Percentage of ownership additional shares 25.00%          
License Agreement [Member]            
Patent and Technology License Agreements [Line Items]            
License agreement development, description       Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. Citius Oncology was required to reimburse Eisai for up to $2.65 million of its costs to complete the Phase 3 pivotal clinical trial for LYMPHIR for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a Biologics License Application (“BLA”) for LYMPHIR.    
Eisai [Member]            
Patent and Technology License Agreements [Line Items]            
Description of license agreement       The royalties will end on the earlier of (i) the 15-year anniversary of the first commercial sale of the latest indication that received regulatory approval in the applicable country and (ii) the date on which a biosimilar product results in the reduction of net sales in the applicable product by 50% in two consecutive quarters, as compared to the four quarters prior to the first commercial sale of the biosimilar product.